Scientific Project Manager

Marion Psomiades

Neurosciences, Rare Diseases, Ophthalmology

“Therapeutic innovation targeting neurodegenerative and neurodevelopmental diseases is a major health issue. At Institut Roche, we are fortunate to work at the interface between Roche Group R&D ecosystem and international academic research groups of excellence to co-construct R&D public-private partnerships in order to faster therapeutic innovations for the benefit of patients. As a scientific project manager, our missions are diverse and exciting: to identify partners and scientific synergies, to co-construct the collaborative project, to ensure scientific follow-up and facilitate collaborator’s relations.”

Your role at Institut Roche and brief presentation of your professional background:

I joined the Institut Roche in 2019, as a Scientific Project Manager. My role is to find synergize between internal (Roche) and external expertise/R&D programs in the world in order to co-develop ambitious public-private research programs in neurosciences, rare diseases and ophthalmology therapeutic areas. Before to join the Institut Roche, I worked on neuropsychiatric conditions such as schizophrenia and depression to understand the neuroplasticity mechanisms and cerebral alterations underlying specific symptomatology such as auditory verbal hallucinations. In addition, I have been trained in non-invasive brain stimulation (NIBS) methods to decrease drug-resistant symptoms in patients.
Fascinated by the behavioral consequences of brain functions, I want to put all my energy and give the best of myself to faster the development of therapeutic solutions targeting the brain to improve patient’s life.

My Focus at Institut Roche:

At the Institut Roche I work mainly on neurodegenerative and neurodevelopmental disorders as well as on ophthalmology, whether the pathologies are rare or more commonly observed.

  1. Psomiades M, Mondino M, Galvão F, Mandairon N, Nourredine M, Suaud- Chagny MF, Brunelin J. Serum Mature BDNF Level Is Associated with Remission Following ECT in Treatment-Resistant Depression. Brain Sci. 2022 Jan 18;12(2):126.
  2. Suaud-Chagny MF, Mondino M, Brunelin J. Frontotemporal Transcranial Direct Current Stimulation Decreases Serum Mature Brain-Derived Neurotrophic Factor in Schizophrenia. Brain Sci. 2021 May 19;11(5):662
  3. Adam O*, Psomiades M*, Rey R, Mandairon N, Suaud-Chagny MF, Mondino M, Brunelin J. Frontotemporal Transcranial Direct Current Stimulation Decreases Serum Mature Brain-Derived Neurotrophic Factor in Schizophrenia. Brain Sci. 2021 May 19;11(5):662.
  4. Psomiades M et al., N-Acetyl-Aspartate in the dorsolateral prefrontal cortex in men with schizophrenia and auditory verbal hallucinations: A 1.5 T Magnetic Resonance Spectroscopy Study. Sci Rep. 2018 Mar 7;8(1) :4133.
  5. Psomiades M et al., Integrity of the arcuate fasciculus in patients with schizophrenia with auditory verbal hallucinations: A DTI-tractography study. NeuroImage: clinical, 2016 May 3;12:970-975
  6. Psomiades M et al., Early Serum BDNF level changes predict remission in patients with treatment-resistant depression receiving electroconvulsive therapy. Preliminary Evidence. Biol Psychiatry. 2016, Volume 79, Issue 9, S281 – S416:401S [10.799]
  7. Psomiades M et al., Neurostimulation du cortex préfrontal dorsolatéral : quels effets sur la symptomatologie et les émotions dans la dépression et la schizophrénie ? Sante Ment Que. 2016 Spring;41(1):223-39

*Share first authorship

More publications